Astellas Pharma Dividends and Buybacks
Dividend criteria checks 4/6
Astellas Pharma is a dividend paying company with a current yield of 4.8%. Next payment date is on 3rd June, 2025 with an ex-dividend date of 28th March, 2025.
Key information
4.8%
Dividend yield
0.3%
Buyback Yield
| Total Shareholder Yield | 5.1% |
| Future Dividend Yield | 5.3% |
| Dividend Growth | 7.8% |
| Next dividend pay date | 03 Jun 25 |
| Ex dividend date | 28 Mar 25 |
| Dividend per share | JP¥74.000 |
| Payout ratio | 350% |
Recent dividend and buyback updates
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00
Dec 04
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Sep 24Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Sep 03Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Aug 20Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 26Recent updates
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00
Dec 04Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Nov 06Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think
Nov 01Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors
Oct 15Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Sep 24Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Sep 03Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Aug 20Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 04Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 26Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year
Jul 11Is Astellas Pharma (TSE:4503) A Risky Investment?
Jun 14Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear
May 02Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 29Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price
Feb 29Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 4503's dividends per share have been stable in the past 10 years.
Growing Dividend: 4503's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Astellas Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (4503) | 4.8% |
| Market Bottom 25% (JP) | 1.8% |
| Market Top 25% (JP) | 3.8% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (4503) (up to 3 years) | 5.3% |
Notable Dividend: 4503's dividend (4.8%) is higher than the bottom 25% of dividend payers in the JP market (1.82%).
High Dividend: 4503's dividend (4.8%) is in the top 25% of dividend payers in the JP market (3.83%)
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (350.2%), 4503's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (105.4%), 4503's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 16:24 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Astellas Pharma Inc. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |